MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5
Clinical safety rating
cautionComprehensive clinical and safety monograph for MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 (MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5).
Administration of electrolytes to correct deficiencies or maintain homeostasis; no pharmacological target.
| Metabolism | Electrolytes are not metabolized; excreted primarily by kidneys. |
| Excretion | Electrolytes are primarily eliminated via renal excretion ( >95% ). Biliary/fecal elimination is negligible (<5%). |
| Half-life | The half-life is not applicable as a single value because electrolytes are homeostatically regulated. For potassium, the terminal elimination half-life is approximately 12 hours in healthy individuals, but it is highly dependent on renal function and serum levels. |
| Protein binding | Electrolytes are minimally protein-bound: Sodium <5%, Potassium <5%, Calcium ~40-50% (bound to albumin), Magnesium ~30% (bound to albumin), Chloride <5%, Bicarbonate <5%. |
| Volume of Distribution | Sodium: 0.6-0.7 L/kg (primarily extracellular); Potassium: 4-5 L/kg (mainly intracellular); Calcium: 0.3-0.5 L/kg; Magnesium: 0.5-0.7 L/kg. Reflects distribution into body fluid compartments. |
| Bioavailability | Intravenous: 100%. Not administered via other routes; oral supplementation is available separately. |
| Onset of Action | Intravenous administration: Immediate (within seconds to minutes) as electrolytes directly enter the bloodstream. |
| Duration of Action | Duration depends on the specific electrolyte and patient's homeostasis. For example, potassium replacement effects last hours to days; continuous infusion is often needed to maintain levels. Clinical monitoring required. |
| Molecular Weight | Multiple components: Sodium chloride 58.44, Potassium chloride 74.55, Calcium chloride dihydrate 147.02, Magnesium chloride hexahydrate 203.30, Sodium acetate trihydrate 136.08; no single MW. |
Intravenous administration of 500-1000 mL at a rate of up to 1 L/hour, adjusted based on electrolyte status and fluid balance.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in anuria or severe renal impairment (GFR <30 mL/min) due to risk of electrolyte overload. For GFR 30-60 mL/min, reduce infusion rate and monitor electrolytes closely. |
| Liver impairment | No specific Child-Pugh based dose adjustments; however, monitor for electrolyte disturbances, particularly in severe hepatic impairment (Child-Pugh C) due to altered metabolism. |
| Pediatric use | Intravenous dosing based on weight: 20-30 mL/kg/day, adjusted according to serum electrolyte levels and clinical condition. Infuse at a rate not exceeding 5 mL/kg/hour. |
| Geriatric use | Use with caution due to age-related decline in renal function; start with lower infusion rates (e.g., 250-500 mL over 2-4 hours) and monitor renal function and electrolytes frequently. |
| 1st trimester | This is a balanced electrolyte solution; administration is considered safe when clinically indicated. No known teratogenic effects at therapeutic doses. |
| 2nd trimester | Safe when used as clinically indicated. Monitor maternal electrolytes and fluid balance. |
| 3rd trimester | Safe when used as clinically indicated. Monitor maternal electrolytes and fluid balance; avoid fluid overload. |
Clinical note
Comprehensive clinical and safety monograph for MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5 (MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5).
| Placental transfer | Electrolytes (sodium, potassium, calcium, magnesium, chloride, acetate) readily cross the placenta by passive diffusion and active transport to maintain fetal homeostasis. |
| Breastfeeding | Electrolytes are normal constituents of human milk. Administration of this solution to the mother does not pose a risk to the nursing infant. Use as clinically indicated. |
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | No teratogenic risk; electrolytes are physiologic substances and essential for normal fetal development. No increased risk of congenital anomalies at therapeutic doses. |
| Fetal Monitoring | Monitor maternal serum electrolyte levels, acid-base balance, renal function, and fluid status. Fetal heart rate monitoring if maternal electrolyte disturbances occur. No specific fetal surveillance required for normal use. |
| Fertility Effects | No known adverse effects on fertility; electrolytes are essential for normal reproductive function. Therapeutic doses do not impair fertility. |
■ FDA Black Box Warning
None.
| Serious Effects |
HyperkalemiaHypercalcemiaHypermagnesemiaSevere renal impairment with oliguriaAddison's diseaseEdema with sodium retention
| Precautions | Monitor serum electrolytes, fluid balance, and acid-base status, Use with caution in patients with renal impairment, heart failure, or conditions predisposing to fluid/electrolyte disturbances, Risk of hyperkalemia with potassium-containing solutions, Risk of hypercalcemia if calcium is present |
| Food/Dietary | No specific food interactions known. However, dietary intake of electrolytes may need adjustment based on serum levels and underlying conditions. Patients on this IV therapy should follow their healthcare provider's dietary recommendations regarding salt and fluid intake. |
| Clinical Pearls | Multiple Electrolytes Injection Type 1 USP pH 5.5 is a sterile, nonpyrogenic solution of electrolytes in water for injection, containing sodium chloride, potassium chloride, calcium chloride, and magnesium chloride. It is used for fluid and electrolyte replacement. Monitor serum electrolytes, renal function, and cardiac status during administration. Avoid in patients with hyperkalemia, hypercalcemia, hypermagnesemia, or severe renal impairment. Use with caution in heart failure or edema. Check compatibility with other IV fluids and medications. |
| Patient Advice | This injection is given to replace fluids and electrolytes in your body. · You may need regular blood tests to check your electrolyte levels. · Tell your healthcare provider if you have kidney problems, heart disease, or are on a salt-restricted diet. · Report any signs of too much fluid in your body, such as swelling, shortness of breath, or rapid weight gain. · This medication is only given by a healthcare professional. |
Loading safety data…